What is DaVita?
Kidney care and dialysis company with $13.643B of 2025 revenue and enterprise healthcare scale.
- Category
- Kidney care and dialysis
- Headquarters
- Denver, CO
- Founded
- 1999
- Employees
- 76,000+
- Total funding
- Public company; no VC funding
- Status
- NYSE: DVA; ~$10B market cap
What is DaVita?
DaVita is a public kidney care and dialysis company headquartered in Denver, CO. It reported $13.643B of 2025 revenue and operates at global enterprise scale.
DaVita operates in kidney care and dialysis with a portfolio spanning U.S. dialysis, related lab and pharmacy services, integrated kidney care, and international operations. The company reported $13.643B of 2025 revenue, employs about 76,000+, and trades as NYSE: DVA. Its customer base is large, regulated, and relationship-driven, with purchasing decisions shaped by clinical outcomes, compliance, reimbursement, operating leverage, and long-term supply reliability.
The company's scale comes from durable demand in healthcare, recurring consumables or services, installed bases, payer or provider relationships, and disciplined capital allocation. Unlike early-stage software companies, DaVita is evaluated through revenue growth, margins, cash flow, reimbursement exposure, procedure or prescription volume, quality, and regulatory execution.
For sellers, DaVita is not a single buying center. The practical map includes procurement, finance, clinical, IT, security, compliance, operations, supply chain, commercial teams, and business-unit executives. Strong pitches connect directly to patient outcomes, cost-to-serve, risk reduction, revenue capture, uptime, or measurable productivity.
What does DaVita offer?
DaVita offers healthcare products and services across U.S. dialysis, related lab and pharmacy services, integrated kidney care, and international operations.
- In-center dialysis· Kidney care
- Home dialysis· Kidney care
- Integrated kidney care· Value-based care
- Physician partnerships· Provider network
- Patient education· Services
- International dialysis· Global
How does DaVita make money?
DaVita earns revenue by providing dialysis and kidney-care services reimbursed by commercial payers, Medicare, Medicaid, and value-based care contracts.
DaVita earns revenue by providing dialysis and kidney-care services reimbursed by commercial payers, Medicare, Medicaid, and value-based care contracts. In 2025, that model produced $13.643B of revenue, showing the scale of the installed base, service footprint, payer/provider contracts, or distribution volume behind the business.
Pricing is reimbursement-, payer-contract-, modality-, clinic-, quality-, and risk-arrangement driven; commercial mix, Medicare rates, patient acuity, labor, and pharmaceuticals materially affect unit economics. That makes the relevant "pricing tier" for sellers an enterprise contracting motion: account segmentation, compliance review, value analysis, legal terms, security review, reimbursement impact, and multi-year renewal economics.
Growth is driven by a mix of market expansion, procedure or prescription volume, product launches, acquisitions, geographic reach, contract renewals, operational efficiency, and technology adoption. Vendors should expect rigorous procurement, documented ROI, data-security requirements, and evidence that the product can work inside regulated healthcare operations.
Who leads DaVita?
DaVita is led by Javier Rodriguez, with finance, operations, clinical, technology, and business-unit leaders shaping major enterprise decisions.
- Javier RodriguezChief Executive OfficerCEO since 2019Longtime DaVita executive leading dialysis and integrated kidney care.
- Joel AckermanChief Financial Officer and TreasurerCFO since 2017Finance leader for clinic economics and capital allocation.
- Kathleen WatersChief Legal and Public Affairs OfficerSenior executive leadershipLeads legal, compliance, and public-policy matters.
- Kenny GardnerChief People OfficerSenior executive leadershipWorkforce leader in a labor-intensive care model.
How do you contact DaVita's leadership?
DaVita publishes investor-relations, media, supplier, customer, and compliance channels, but it does not publish verified personal executive emails for the listed leaders. Use the public investor-relations route (ir@davita.com) or official contact forms rather than guessed personal addresses.
ir@davita.com is a public investor/contact route; personal executive email format not verifiedSources:DaVita contactDaVita leadership
How much funding has DaVita raised?
DaVita is a mature public company, not a venture-backed startup. It trades as NYSE: DVA, had an approximate ~$10B market capitalization in June 2026, and funds growth through operating cash flow, debt markets, public equity access, and acquisition capacity.
DaVita's capital history is a public-company story rather than a disclosed venture-round history. The relevant milestones are founding in 1999, public-market access, acquisitions, debt capacity, dividends or buybacks where applicable, and reinvestment in regulated healthcare capabilities.
The company reported $13.643B of 2025 revenue and operates with the financing tools expected of a large public healthcare company. Capital is directed toward product development, clinical evidence, facilities, inventory, technology, acquisitions, compliance, reimbursement capabilities, and shareholder returns depending on the business model.
Seller signal: DaVita has meaningful buying power, but budget access is tied to risk, ROI, compliance, and executive sponsorship. Vendors should map proposals to cost reduction, growth, care quality, automation, supply resilience, cybersecurity, data quality, or measurable operating improvement.
How did DaVita get here?
DaVita grew through founding, public-market scale, product expansion, acquisitions, and healthcare-market execution.
- 1999Total Renal Care restructuredThe company is reorganized and later becomes DaVita.
- 2000DaVita name adoptedThe company begins building a national kidney-care brand.
- 2012HealthCare Partners acquiredDaVita expands into physician and value-based care.
- 2019Medical group soldDaVita refocuses on kidney care after selling DaVita Medical Group.
- 2025$13.643B revenueDaVita reports full-year 2025 consolidated revenue.
- 202525-year milestoneDaVita marks 25 years as a kidney-care operator.
Who are DaVita's competitors?
DaVita competes with companies that overlap in customers, budgets, clinical categories, distribution channels, or healthcare services.
- Fresenius Medical CareLargest global dialysis-products and services competitor.
- U.S. Renal CareU.S. dialysis provider competitor.
- American Renal AssociatesDialysis clinic competitor now under Innovative Renal Care.
- Fresenius Medical CareGlobal dialysis and kidney-care provider competing with DaVita in renal-care services.
- SomatusValue-based kidney and home-care competitor.
DaVita — frequently asked questions
